ANNUAL REPORT FY2025 9 “With the Phase I trial complete and additional therapeutic indications under active evaluation, our strategic focus is now on the planning and execution of a Phase IIa clinical trial.”
Made with FlippingBook
RkJQdWJsaXNoZXIy MjE2NDg3